The place of inhibitor-protected penicillins in the treatment of lower respiratory tract infections

The main nosological forms of lower respiratory tract infections are infectious exacerbation of chronic bronchitis, chronic obstructive pulmonary disease (COPD) and community-acquired pneumonia (CAP). The relevant antibacterial drugs in the above-mentioned diseases are b-lactam antibiotics (aminopenicillins including inhibitor-protected penicillins, II-III generation cephalosporins), macrolides, respiratory fluoroquinolones. Inhibitor-protected penicillins, macrolides, and respiratory fluoroquinolones are similar in their clinical and microbiological efficacy. When choosing the antibacterial drug, it is necessary to take into account the clinical case, in particular, the severity of acute exacerbations of chronic bronchitis, COPD and CAP, poor response factors, risk of antibiotic resistance, ease of dosing regimens, safety and tolerability of the antibacterial drug